Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study

Phase 2

• Conditions: Keratoconjunctivitis Sicca; Dry Eye Syndrome
• Interventions: Drug: Pro-ocular™ Topical Gel; Drug: Placebo Topical Gel

• Registration Number: NCT04884217
• Lead Sponsor: PharmaDax Inc.

Brief Summary

To evaluate the safety and efficacy of 1% Pro-ocular topical gel administered twice daily for 12 weeks in treatment of Dry Eye Disease

Detailed Description

Pro-ocular™ 1% topical gel his demonstrated efficacy in rapidly reducing or eliminating dry eye symptoms, and after multiple doses, the signs and symptoms of ocular surface disease including dry eye disease.

Study DE-2 is single center, randomized, double-masked, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of 1% Pro-ocular topical gel administered twice daily for 12 weeks for treatment of Dry Eye Disease. The approximately 80 subjects will be randomized 1:1, active drug:placebo.

Study Timeline

• Status Verified: 2021-05
• Study First Submitted: 2021-05-10
• Study First Submitted QC: 2021-05-10
• Study First Posted: 2021-05-12
• Last Update Submitted: 2021-05-12
• Last Update Posted: 2021-05-14
• Study Start: 2021-05-20
• Primary Completion: 2021-10-30
• Study Completion: 2021-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Male or female of any race, at least 20 years of age at Visit 1 Screening.

2. Has a subject reported history (including physician diagnosis) of dry eye disease in both eyes for at least 3 months prior to Visit 1.

3. Has SANDE score ≥50 in either frequency or severity of symptoms of dryness and/or irritation at Visit 1.

4. Have all of the following in the same eye at Visit 1:

   1. Fluorescein Tear Break-Up Time of ≤5 seconds.
   2. Corneal fluorescein staining score of moderate or more in any field (inferior, superior or central).
   3. Report a severity score of moderate or more on ocular dryness and at least one of the other symptoms on the GLIA Ocular Surface Disease Symptoms Questionnaire.

5. Has provided written informed consent.

6. Be able and willing to follow oral and written instructions, including participation in all study assessments and visits.

Exclusion Criteria

1. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assessments, such as but not limited to corneal opacities and scars, dystrophies, epithelial scarring, infections, history of blood clots, etc.
2. Has infections, or inflammatory skin lesion in or around the dosing area.
3. Best corrected visual acuity baseline <20/200.
4. Has a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study.
5. Wear contact lens within 7 days prior to Visit 1.
6. Anticipate change of vision correction or anticipate any ocular procedures during study period.
7. A woman who is pregnant or testing positive in the blood pregnancy test at screening, nursing an infant, or planning a pregnancy.
8. Has a known adverse reaction and/or sensitivity to the study drug or its components.
9. Use of topical ocular cyclosporine (e.g. Restasis®), lifitegrast (Xiidra®), diquafosol (Diquas®), eye gels, eye ointments, any administration route of steroids, anti-histamines, antipsychotics, antidepressants and NSAIDs within 30 days prior to Visit 1.
10. Routine use (more than once a week) of a chlorinated swimming pool during study period.
11. Unwilling or unable to cease using the following medications during the study period (from Visit 1 to Visit 6): Topical ocular cyclosporine (e.g. Restasis®), lifitegrast (Xiidra®), diquafosol (Diquas®), eye gels, eye ointments, any administration route of steroids, anti-histamines, antipsychotics, antidepressants and NSAIDs..
12. Unwilling to cease the use of sunscreen and face scrubs on the forehead or eye area during study period.
13. Smoke within 3 months prior to Visit 1.
14. Ongoing glaucoma treatment within 30 days prior to Visit 1 and during study period.
15. Currently enrolled in an investigational drug or device study within 30 days prior to Visit 1 and during study period.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pro-ocular™	Pro-ocular™ Topical Gel	Pro-ocular™ Topical Gel
Placebo	Placebo Topical Gel	Placebo Topical Gel

Primary Outcome Measures

Name	Time	Method
Change in SANDE (Symptom Assessment iN Dry Eye) Questionnaire Frequency score	2 weeks	Change from baseline in SANDE symptoms frequency score (0-100 worst)
Change in corneal (central) fluorescein staining score	4 weeks	Change from baseline in score on a visual analog scale (0-10 worst)

Secondary Outcome Measures

Name	Time	Method
Change in GLIA (Ocular Surface Disease Symptoms Questionnaire) ocular discomfort score	12 weeks	Change from baseline in GLIA OSDSQ ocular discomfort score (0-10 worst)
Change in SANDE (Symptom Assessment iN Dry Eye) Questionnaire Frequency score	12 weeks	Change from baseline in SANDE symptoms frequency score (0-100 worst)
Change in SANDE (Symptom Assessment iN Dry Eye) Questionnaire Severity score	12 weeks	Change from baseline in SANDE symptoms severity score (0-100 worst)
Change in Bulbar redness score by Keratograph®	12 weeks	Change from baseline in Bulbar redness score (highest is worst)
Change in corneal (superior) fluorescein staining score	12 weeks	Change from baseline in superior corneal fluorescein staining score (0-10 worst)
Change in corneal fluorescein staining sum of scores	12 weeks	Change from baseline in corneal fluorescein staining sum of scores (0-30 worst)
Change in GLIA (Ocular Surface Disease Symptoms Questionnaire) sum of scores	12 weeks	Change from baseline in GLIA OSDSQ sum of scores (highest worst)
Change in Meibography score by Keratograph®	12 weeks	Change from baseline using Grades 0 to 3 (0 no loss to 3 \>2/3 loss)
Change in Tear Meniscus Height (TMH) by Keratograph®	12 weeks	Change from baseline in mm TMH (higher is better)
Change in corneal (central) fluorescein staining score	12 weeks	Change from baseline in central corneal fluorescein staining score (0-10 worst)
Change in lissamine green staining (corneal and conjunctival) sum of scores	12 weeks	Change from baseline in lissamine green staining (corneal and conjunctival) sum of scores (higher is worse)
Change in conjunctival hyperemia (by slit lamp biomicroscopy)	12 weeks	Change from baseline in conjunctival hyperemia score (0-10 worst)
Change in conjunctival fluorescein staining sum of scores	12 weeks	Change from baseline in conjunctival fluorescein staining sum of scores (0-30 worst)
Change in SANDE (Symptom Assessment iN Dry Eye) Questionnaire Global score	12 weeks	Change from baseline in SANDE symptoms global score (0-100 worst)
Change in Tear Film Grading by TearScan examination	12 weeks	Change from baseline in tear film grade (0-3 best)
Change in Non-Invasive Keratograph® Tear Break-Up Time (NIKBUT)	12 weeks	Change from baseline in NIKBUT in seconds (longer is better)
Change in corneal (inferior) fluorescein staining score	12 weeks	Change from baseline in inferior corneal fluorescein staining score (0-10 worst)
Change in tear film osmolarity by TearLab™ osmolarity system	2 weeks	Change from baseline in mOsms/L (higher value is less sensitive)
Change in corneal sensitivity using Cochet-Bonnet esthesiometer	12 weeks	Change from baseline in mm Hg (higher is less sensitive)
Change in Fluorescein Tear Break-Up Time (FBUT)	12 weeks	Change from baseline in FBUT in seconds (longer is better)

Trial Locations

Locations (1)

Tri-Service General Hospital, National Defense Medical Center; 🇨🇳 Taipei City, Taiwan